Study compares ‘alternative’ donor source vs. traditional transplantation of blood stem cells from an adult, unrelated donor
Sept. 7, 2016
| By Rachel Tompa / Fred Hutch News Service
A new study by Fred Hutch researchers, published today in The New England Journal of Medicine, has found that umbilical cord blood transplants may have advantages beyond being an alternative source of stem cells for patients without a traditional donor match. They also are associated with a lower risk of relapse in high-risk leukemia patients.
Dr. Colleen Delaney leads first test of "off-the-shelf" cord blood cell product outside the transplant setting; Dr. Justin Taylor receives Hartwell Foundation award to research alternative to RSV vaccine
Drs. Colleen Delaney, Harlan Robins named 2016 Leaders in Health Care; Hutch study finds CMV viral load can act as surrogate endpoint for clinical trials; A new target for Tumor Paint: BLZ-100 lights up head and neck cancers; Dr. Stephen Tapscott appointed to NIAMS advisory council
New Fred Hutch spinoff to commercialize cord blood stem cell therapies based on work by Drs. Colleen Delaney, Irwin Bernstein
Dec. 3, 2015
| By Susan Keown / Fred Hutch News Service
A new Fred Hutch spinoff, Nohla Therapeutics, will commercialize cord blood stem cell therapies based on work by Dr. Colleen Delaney and Dr. Irwin Bernstein. In preliminary studies, the company’s first product helps stem cells engraft more quickly after transplant and protects patients from deadly infections during this vulnerable period.